Peripheral nerve repair is entering a new phase of clinical recognition, and Axogen Inc. (AXGN) is positioned at the center of that shift. With growing support from surgical societies and expanding payer coverage, the company's biologic platform is gaining traction.
At the heart of its strategy is Avance Nerve Graft, a product now approaching a critical regulatory milestone that could reshape its commercial trajectory.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com